Anzeige
Mehr »
Montag, 31.08.2026 - Börsentäglich über 12.000 News
Kupfer auf Rekordhoch: Bohrkern unterm Mikroskop - bei dieser Kupfer-Aktie könnte jetzt das Labor den wichtigen Unterschied machen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
205 Leser
Artikel bewerten:
(0)

Amai Proteins' sweelin Approved for Sale in Israel, Opening the Market to a New Generation of Reduced-Sugar Food and Beverage Products

Third regulatory approval in less than six months enables food and beverage manufacturers to commercialize products sweetened with sweelin in Israel.

REHOVOT, Israel, Aug. 31, 2026 /PRNewswire/ -- Amai Proteins announces that the Israeli Ministry of Health has officially approved sweelin as a novel food ingredient for use in a broad range of food and beverage products. Food and beverage manufacturers can now formulate and commercialize products containing sweelin in the Israeli market.

The approval (https://www.gov.il/he/pages/fcs-304778726) follows recent regulatory clearances in the United States and Singapore, making Israel the third market to authorize the commercial use of sweelin in less than six months.

The Israeli Ministry of Health determined that sweelin is safe for its intended use, and its guidance authorizes sweelin for use in more than 25 food and beverage categories.

sweelin is a precision-fermented clean-tasting sweet protein designed to help manufacturers significantly reduce sugar or other conventional sweeteners, while maintaining excellent taste and aligning with growing demand for clean-label and GLP-1 friendly products.

A New Tool for Product Innovation

The approval gives Israeli food and beverage manufacturers immediate access to a new sweetening technology that supports healthier product development without compromising taste or manufacturing performance.

sweelin offers manufacturers several important advantages:

  • Up to 70% sugar reduction across a wide range of food and beverage applications.
  • Excellent clean taste.
  • High sweetness potency (on average 3000x sweeter than sugar), enabling very low use levels.
  • Protein-based ingredient produced through precision fermentation.
  • Compatibility with industrial food processing.
  • Published clinical evidence demonstrating no effect on blood glucose, insulin, or GLP-1 levels.

"Receiving regulatory approval in Israel is an important commercial milestone for Amai Proteins," said Dr. Amir Guttman, CEO of Amai Proteins.

"We are especially proud that sweelin is the first sweet protein approved in Israel. As an Israeli company, we are excited to make this innovative ingredient available to local food and beverage manufacturers and help them develop healthier products without compromising on taste. We thank the Israeli Ministry of Health for its thorough scientific review and for confirming the safety of sweelin."

Building Global Commercial Momentum

The Israeli approval follows several important milestones achieved during 2026:

  • United States: FDA GRAS Approved
  • Singapore: Singapore Food Agency (SFA) approval for use as a sweetening agent.
  • Clinical Validation: world's first published human clinical study on a sweet protein, demonstrating that sweelin does not increase blood glucose, insulin, or GLP-1 levels.

With regulatory approvals now spanning three international markets, Amai Proteins is actively working with food and beverage manufacturers to commercialize products containing sweelin.

About Amai Proteins

Amai Proteins develops, scales and commercializes proprietary sweet proteins for the food, beverage, and dietary supplement industries. The company's technology platform combines precision fermentation and advanced food technology to develop scalable, high-performance and great tasting protein ingredients.

Amai's lead product, sweelin, is a monellin-based sweet protein inspired by the serendipity berry and is on average 3,000 times sweeter than sugar on a weight basis. The product is designed for stability, affordability, and compatibility with industrial food processing applications.

Produced through precision fermentation, sweelin can be used in a wide variety of food & beverages, confectionery, chewing gum, condiments, and dietary supplements. Amai works with leading food and supplement manufacturers to enable up to 70% sugar reduction without compromising taste, cost, or sustainability.

For more information, visit www.amaiproteins.com.

Media Contact

Dr. Amir Guttman
Chief Executive Officer
Amai Proteins
press@amaiproteins.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/amai-proteins-sweelin-approved-for-sale-in-israel-opening-the-market-to-a-new-generation-of-reduced-sugar-food-and-beverage-products-302864387.html

© 2026 PR Newswire
KI braucht Strom
Halbleiter, Speicherchips und Rechenzentren haben Anlegern im KI-Boom bereits enorme Gewinne beschert. Doch jetzt zeichnet sich mit der benötigten Energie der nächste große Flaschenhals ab. Neue KI-Rechenzentren benötigen nicht mehr einige Megawatt, sondern zum Teil mehrere Gigawatt Leistung – so viel wie mehrere moderne Kernkraftwerksblöcke.

Damit beginnt ein weltweites Wettrennen um verfügbare Stromkapazitäten. Hyperscaler sichern sich bereits über langfristige Verträge gewaltige Energiemengen, während Stromnetze und Erzeugungskapazitäten mit dem Ausbau kaum Schritt halten können. Zusätzlich verschärfen geopolitische Risiken rund um den Iran-Krieg und die Straße von Hormus die Situation.

Für Energieversorger und ihre Zulieferer könnte damit ein goldenes Zeitalter beginnen. Steigende Nachfrage, langfristige Abnahmeverträge und wachsende Strompreise schaffen ein Umfeld, in dem ausgewählte Unternehmen zum nächsten großen KI-Trade werden könnten.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die besonders stark vom explodierenden Energiehunger der KI profitieren könnten – und bei Anlegern bislang teilweise noch unter dem Radar laufen.

Jetzt den kostenlosen Report sichern – und die nächsten Gewinner des KI-Booms entdecken!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.